Wednesday, July 8, 2026

pharma · Menopause · Vulvovaginal Atrophy · TXMD

TherapeuticsMD

TherapeuticsMD clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Boca Raton, USA HQ
53 Employees
Public company Type
TXMD · NYSE Ticker
Company details
Status
Public
HQ
Boca Raton, USA
Employees
53
Programs
6
Drugs
6
Patents
0
Intelligence · Clinical Programs

TherapeuticsMD projects

6 ClinicalTrials.gov programs sponsored by TherapeuticsMD.

TherapeuticsMD has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Estradiol

    TherapeuticsMD

    Menopause

    phase 3 small molecule completed

    2 trials
  2. Estradiol

    TherapeuticsMD

    Vulvovaginal Atrophy

    phase 3 small molecule completed

    1 trial
  3. Progesterone

    TherapeuticsMD

    Secondary Amenorrhea

    phase 3 small molecule terminated

    1 trial
  4. oral estradiol 1.0 mg

    TherapeuticsMD

    Menopause

    phase 3 small molecule completed

    1 trial
  5. Segesterone Acetate and Ethinyl Estradiol

    TherapeuticsMD

    Contraception

    phase 1 small molecule completed

    1 trial
  6. Segesterone Acetate and Ethinyl Estradiol

    TherapeuticsMD

    Women

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does TherapeuticsMD have?

6 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.